How Barry Sherman built Apotex on patent challenges, what followed the 2017 murders, and what the June 2026 TSX IPO reveals about Canada’s largest drug maker.
Startup · Topic
Canada Healthcare, Cannabis & Life Sciences
Expert guides, analysis and tool comparisons on Canada Healthcare, Cannabis & Life Sciences from the kurums.com Startup desk — written for business decision-makers and updated as the market moves.
- 5 guides
- Updated Oct 20, 2026
Latest in Canada Healthcare, Cannabis & Life Sciences
Telus Health, Maple and the Private-Medicine Debate Inside Canada’s Public System
Telus Health’s LifeWorks deal, Maple’s paid virtual visits and the LifeLabs sale explain where private money is allowed inside Canada’s public health system.
Bausch Health: Living With Valeant’s Legacy of Debt, Xifaxan and a Stalled Bausch + Lomb Split
Valeant’s roll-up, its collapse, and Bausch Health’s decade-long turnaround: US$20bn of debt, Xifaxan’s 2028 patent cliff and the unfinished Bausch + Lomb split.
AbCellera and Vancouver’s Biotech Cluster: From COVID Antibodies to a Long Rebuild
How AbCellera turned a COVID antibody windfall into an internal pipeline, and why Zymeworks, Xenon and Stemcell make Vancouver Canada’s leading biotech cluster.
Canada’s Cannabis Bust: How Canopy Growth, Tilray and Aurora Burned Billions After Legalisation
From Constellation’s C$5bn Canopy bet to Curaleaf’s hostile bid for Aurora: how Canada’s cannabis boom turned into a bust and what survivors look like in 2026.
All guides
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
